Valuation Silence Therapeutics plc OTC Markets
Stocks
SLNCF
GB00B9GTXM62
Biotechnology & Medical Research
|
Market Closed -
OTC Markets
15:14:54 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 6.520 USD | +2.35% |
|
+2.35% | +226.00% |
| 10-19 | Health Care Up on Deal Activity - Health Care Roundup | DJ |
| 10-19 | Silence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares Surge | MT |
Company Valuation: Silence Therapeutics plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 528 | 454.3 | 527.3 | 259.5 | 213.4 | 887.8 | - | - |
| Change | - | -13.96% | 16.08% | -50.8% | -17.76% | 316.09% | - | - |
| Enterprise Value (EV) 1 | 454.5 | 454.3 | 473.6 | 163.4 | 149.5 | 753.5 | 712.1 | 655.5 |
| Change | - | -0.04% | 4.24% | -65.49% | -8.53% | 403.97% | -5.49% | -7.94% |
| P/E | -13.7x | -9.99x | -11.6x | -6.95x | -3.22x | -38.7x | -31.9x | -24.4x |
| PBR | - | - | 29.5x | -7.12x | 13.8x | 19.8x | 13.3x | 10.6x |
| PEG | - | 0.8x | 4.94x | 0.2x | -0x | 0.5x | -1.5x | -0.8x |
| Capitalization / Revenue | 42.5x | 26x | 20.8x | 7.57x | 510x | 2,701x | 1,168x | 5,128x |
| EV / Revenue | 36.6x | 26x | 18.7x | 4.77x | 357x | 2,292x | 936x | 3,786x |
| EV / EBITDA | -10x | -9.44x | -9.64x | -3.29x | -2.2x | -16.7x | -11.8x | -8.46x |
| EV / EBIT | -9.92x | -9.35x | -9.55x | -3.26x | -2.19x | -16.7x | -10.9x | -7.57x |
| EV / FCF | 419x | -9.96x | -10.4x | -3.04x | -3x | -22.4x | -10.2x | -7.44x |
| FCF Yield | 0.24% | -10% | -9.63% | -32.9% | -33.4% | -4.45% | -9.77% | -13.4% |
| Dividend per Share 3 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 3 | -1.742 | -1.527 | -1.491 | -0.99 | -1.89 | -0.51 | -0.62 | -0.81 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 12.42 | 17.5 | 25.38 | 34.27 | 0.4183 | 0.3288 | 0.7604 | 0.1732 |
| EBITDA 1 | -45.39 | -48.11 | -49.11 | -49.69 | -68.06 | -45.15 | -60.24 | -77.53 |
| EBIT 1 | -45.81 | -48.59 | -49.6 | -50.16 | -68.16 | -45.2 | -65.14 | -86.63 |
| Net income 1 | -39.41 | -40.49 | -43.27 | -35.89 | -66.32 | -42.57 | -64.86 | -88.47 |
| Net Debt 1 | -73.54 | - | -53.76 | -96.03 | -63.87 | -134.4 | -175.8 | -232.3 |
| Reference price 3 | 23.89 | 15.25 | 17.37 | 6.88 | 6.08 | 19.76 | 19.76 | 19.76 |
| Nbr of stocks (in thousands) | 29,928 | 35,893 | 38,670 | 47,215 | 47,234 | 60,209 | - | - |
| Announcement Date | 3/17/22 | 3/15/23 | 3/13/24 | 2/27/25 | 3/5/26 | - | - | - |
1USD in Million2GBP in Million3USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.97x | 6.42x | 12.3x | 1.76% | 64.38B | |
| 30.03x | 8.21x | 26.91x | 0.04% | 56.16B | |
| 37.32x | 6.62x | 19.78x | 0.87% | 54.16B | |
| 35.94x | 3.4x | 14.66x | -.--% | 45.33B | |
| 49.01x | 5.65x | 30.93x | -.--% | 42.25B | |
| -19.75x | 191.25x | -21.04x | -.--% | 40.78B | |
| 46.05x | 8.16x | 27.33x | -.--% | 33.8B | |
| 31.61x | 8.04x | 20.91x | 0.41% | 32.25B | |
| 27.18x | 5.72x | 14.84x | -.--% | 23.57B | |
| Average | 28.26x | 27.05x | 16.29x | 0.34% | 43.63B | |
| Weighted average by Cap. | 27.79x | 25.71x | 16.39x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SLN Stock
- SLNCF Stock
- Valuation Silence Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
